Tuesday, June 18, 2013 3:14:27 PM
Posted by: Shayan Afkhami Posted date: June 18, 2013 In: Analyst Articles - US, Investing
Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)‘s stock had its “buy” rating reaffirmed by research analysts at Maxim Group in a report released on Tuesday, TheFlyOnTheWall.com reports. They currently have a $7.00 price target on the stock. Maxim Group’s price objective would suggest a potential upside of 45.83% from the stock’s previous close.
Shares of Tekmira Pharmaceuticals Corp (NASDAQ: TKMR) traded down 1.25% during mid-day trading on Tuesday, hitting $4.74. Tekmira Pharmaceuticals Corp has a one year low of $1.77 and a one year high of $6.78. The stock’s 50-day moving average is currently $4.55.
Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (NASDAQ: TKMR).
http://www.mideasttime.com/tekmira-pharmaceuticals-corps-buy-rating-reaffirmed-at-maxim-group-tkmr/26169/
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM